From: Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase
Patient | Type of leukemia | Genetic aberations | Age | Sex | Percentage of blasts during diagnosis | Peripheral blast count (×109/l) | IC50 ASNase [IU/ml] |
---|---|---|---|---|---|---|---|
P01 | pre-B ALL | KMT2A/MLLT3 | 1 | F | 91% | 161.07 | 0.148802 |
P02 | interT-ALL | none detected | 6 | F | 81% | 51.03 | 0.014910 |
P03 | T-ALL | none detected | 20 | M | 92% | NA | 0.000291 |
P04 | AML M4 | CBFβ-MYH11 | 10 | F | 86% | 122.12 | 0.114985 |
P05 | AML M1 | DEK-NUP214. FLT3-ITD | 17 | M | 85% | 28.82 | 0.000255 |
P06 | pro-B ALL | ETV6-RUNX1 | 11 | F | 93% | 8.18 | 0.040462 |
P07 | AML M4 | NPM1 | 17 | F | 83% | 20.75 | 0.037307 |
P08 | interT-ALL | none detected | 8 | F | 94% | 68.43 | 0.003352 |
P09 | pre-B ALL | IKZF1del | 1 | M | 89% | NA | 0.284902 |
P10 | interT-ALL | none detected | 15 | F | 91% | NA | 0.023467 |
P11 | cALL | none detected | 7 | M | 95% | 40.28 | 0.125948 |
P12 | cALL | ETV6-RUNX1 | 5 | F | 95% | 4.18 | 0.117476 |
P13 | cALL | ETV6-RUNX1 | 3 | M | 84% | 4.20 | 0.001058 |
P14 | cALL | ETV6-RUNX1 | 10 | M | 89% | 3.39 | 0.105594 |
P15 | cALL | ETV6-RUNX1 | 8 | F | 91% | 56.60 | 0.000184 |
P16 | cALL | hyperdiploid | 16 | F | 93% | 26.55 | 0.235677 |
P17 | cALL (partial ProB) | none detected | 8 | F | 97% | 281.30 | > 0.15 |
P18 | T/Myelo | FLT3-ITD | 9 | M | 88% | 9.90 | 0.000242 |
P19 | preT-ALL | none detected | 12 | F | 75% | 139.95 | > 0.15 |
P20 | cALL | ETV6-RUNX1 | 4 | M | 96% | 31.97 | 0.000172 |
P21 | pre-B ALL | none detected | 2 | M | 91% | 108.98 | 0.147981 |
P22 | AML M5 | KMT2A/MLLTA10 | 1 | F | 83% | 366.28 | 0.000181 |
P23 | interT-ALL | none detected | 4 | M | 81% | 93.64 | 0.104566 |
P24 | cALL | ETV6-RUNX1 | 8 | M | 96% | NA | 0.005477 |
P25 | cALL | none detected | 11 | F | 95% | 6.042 | > 0.15 |
P26 | pro-B ALL | KMT2A/AFF1 (MLL-AF4) | < 1 | F | 92% | 404.10 | 0.388752 |
H1 | Healthy B-cells | Â | Â | NA | Â | Â | Resistant |
H2 | Healthy mononuclear cells | Â | Â | NA | Â | Â | Resistant |